)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
HOOKIPA Pharma
HOOKIPA Pharma (HOOK) investor relations material
HOOKIPA Pharma has been delisted
HOOKIPA Pharma Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary28 Feb, 2025
Executive summary
Clinical-stage biopharma focused on arenavirus-based immunotherapeutics for oncology and infectious diseases.
2024 saw a major strategic refocus, pausing eseba-vec (HPV16+ cancer) and HB-300 (prostate cancer) programs, and prioritizing HB-700 (KRAS-mutated cancers) and Gilead-partnered HBV/HIV programs.
Significant restructuring: workforce reduced by ~80%, Vienna operations consolidated, and GMP facility project discontinued.
Financial highlights
Revenue from collaboration and licensing: $43.9M in 2024, up from $20.1M in 2023, mainly due to Roche agreement termination and milestone payments.
Net loss: $43.5M in 2024, improved from $81.6M in 2023.
Research and development expenses: $68.5M in 2024, down from $86.4M in 2023.
Cash, cash equivalents, and restricted cash: $39.9M as of Dec 31, 2024.
Accumulated deficit: $412.8M as of Dec 31, 2024.
Grant income: $7.4M in 2024, mainly from Austrian research incentives.
Outlook and guidance
Substantial doubt exists regarding ability to continue as a going concern for 12 months post-report; additional funding required.
Focus on progressing HB-700 into Phase 1 for KRAS-mutated cancers and advancing Gilead-partnered HBV/HIV programs.
Further cost-saving initiatives and potential capital raises under consideration.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from HOOKIPA Pharma
- Arenavirus immunotherapy platform advances with strong efficacy in HPV16+ and KRAS-mutant cancers.HOOK
Study Update Presentation - Clinical progress and cost cuts offset by ongoing going concern risk and cash decline.HOOKQ3 2024
- Eservivec (HB-200) shows robust efficacy in head and neck cancer, targeting approval by 2027.HOOKH.C. Wainwright 26th Annual Global Investment Conference 2024
- Positive clinical progress and restructuring amid ongoing financial risk.HOOKQ2 2024
- All proposals, including director elections and share structure changes, were approved by shareholders.HOOKAGM 2024
- HB-200 plus pembrolizumab delivers high response rates and durable outcomes in HPV16+ head and neck cancer.HOOKStatus Update
HOOKIPA Pharma
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for cancer and chronic infectious diseases. The company utilizes a proprietary arenavirus platform, pioneering technologies that engineer arenaviruses to elicit robust and durable antigen-specific T cell responses and pathogen-neutralizing antibodies. HOOKIPA's innovative approach aims to reprogram the immune system to more effectively combat diseases, with its diverse pipeline addressing significant unmet medical needs in various therapeutic areas. The company is headquartered in New York, and its shares are listed on the NASDAQ.